Immunis.AI Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$32.2M
- Investors
-
3
Immunis.AI General Information
Description
Developer of a non-invasive blood-based immunogenomic platform discovery platform designed to detect cancer. The company's platform uses machine learning to perform detailed genomic analysis of patient blood samples to understand diseases by analyzing differential gene expression patterns to characterize the disease and identify novel biomarkers and biological pathways, helping clinicians and pharmaceutical developers to improve sensitive small tumor profiling and detect diseases that individuals may be harboring and the body's immune response to those diseases.
Contact Information
Website
immunis.aiCorporate Office
- 1310 North Stephenson Highway
- Suite 101
- Royal Oak, MI 48067
- United States
Corporate Office
- 1310 North Stephenson Highway
- Suite 101
- Royal Oak, MI 48067
- United States
Immunis.AI Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 01-Oct-2021 | $32.2M | Completed | Product Development | ||
| 2. Early Stage VC (Series A) | 15-Aug-2012 | Completed | Startup | |||
| 1. University Spin-Out | 01-Jun-2011 | Completed | Startup |
Immunis.AI Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-2 | ||||||||
| Series A-1 | 49,949,886 | $0.000100 | $0.12 | $0.12 | 1x | $0.12 | 18.71% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Immunis.AI Comparisons
Industry
Financing
Details
Immunis.AI Competitors (5)
One of Immunis.AI’s 5 competitors is GRAIL, a Formerly VC-backed company based in Menlo Park, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GRAIL | Formerly VC-backed | Menlo Park, CA | ||||
| Exact Sciences | Formerly VC-backed | Madison, WI | ||||
| Adaptive Biotechnologies | Formerly VC-backed | Seattle, WA | ||||
| Myriad Genetics | Corporation | Salt Lake City, UT | ||||
| MDxHealth | Formerly VC-backed | Liège, Belgium |
Immunis.AI Signals
Immunis.AI Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Savitr Capital | Venture Capital | Minority | ||
| Remiges Ventures | Venture Capital | Minority | ||
| Harvard University | University |
Immunis.AI FAQs
-
When was Immunis.AI founded?
Immunis.AI was founded in 2011.
-
Where is Immunis.AI headquartered?
Immunis.AI is headquartered in Royal Oak, MI.
-
What is the size of Immunis.AI?
Immunis.AI has 10 total employees.
-
What industry is Immunis.AI in?
Immunis.AI’s primary industry is Discovery Tools (Healthcare).
-
Is Immunis.AI a private or public company?
Immunis.AI is a Private company.
-
What is the current valuation of Immunis.AI?
The current valuation of Immunis.AI is .
-
What is Immunis.AI’s current revenue?
The current revenue for Immunis.AI is .
-
How much funding has Immunis.AI raised over time?
Immunis.AI has raised $42.2M.
-
Who are Immunis.AI’s investors?
Savitr Capital, Remiges Ventures, and Harvard University have invested in Immunis.AI.
-
Who are Immunis.AI’s competitors?
GRAIL, Exact Sciences, Adaptive Biotechnologies, Myriad Genetics, and MDxHealth are competitors of Immunis.AI.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process